A clinical-stage biotech pioneer leveraging proprietary liver-targeting technology to treat severe chronic liver diseases with a robust cash position supporting future R&D expansion.
Investors may view this stock as a high-risk, high-reward opportunity given the proprietary liver-targeting technology that could revolutionize treatment for severe liver diseases. With nearly $200M in cash and a low liability structure, the company has ample resources to advance its pipeline without immediate shareholder dilution. The recent revenue spike suggests strong interest from partners or milestone achievements that could validate the platform before commercial launch.
The stock carries substantial risk due to deep losses of $-74.9M and a massive retained earnings deficit, indicating the company is burning through capital without proven product sales. The lack of current revenue streams makes valuation difficult as success depends entirely on future clinical trial outcomes which are uncertain. Investors should be wary of the volatility seen in net income trends and the heavy reliance on financing activities to sustain operations.
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for severe liver diseases, primarily utilizing its proprietary FULCIR delivery technology. The company serves the global pharmaceutical market with a pipeline targeting conditions like primary biliary cholangitis and other metabolic disorders. While recent data shows significant revenue growth in 2024, the firm remains capital-intensive with substantial cash reserves to fuel its research programs.
Recent financial performance highlights a strategic pivot with revenue surging to $80.0M in 2024, likely driven by milestone payments or licensing deals rather than product sales given the clinical-stage nature. However, the company recorded a net loss of $-74.9M in 2025, supported heavily by cash flow from financing ($168.7M) which increased total cash to $198.7M. The reduction in operating expenses relative to revenue growth suggests improved operational efficiency as the company scales its pre-commercialization activities.
The biopharmaceutical industry for liver disease treatments is competitive but underserved, with few approved therapies for severe conditions like primary biliary cholangitis. Companies in this space face long development timelines and high regulatory hurdles but offer significant upside if a novel mechanism of action proves effective. The sector currently favors firms with proprietary platforms that can differentiate from existing standard-of-care treatments.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $6.3M | $2.8M | $80.0M | $0 |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $6.3M | $2.8M | $80.0M | $0 |
| Operating Expenses | $118.9M | $113.5M | $101.9M | $84.8M |
| Operating Income | $-112.6M | $-110.7M | $-21.9M | $-84.8M |
| R&D | $76.8M | $71.8M | $63.4M | $56.1M |
| G&A | $41.7M | $41.7M | $36.4M | $28.7M |
| Stock-Based Comp | $13.3M | $14.8M | $14.6M | $12.5M |
| Depreciation | $2.4M | $2.2M | $1.6M | $1.4M |
| Other OpEx | $427.0K | $0 | $2.1M | $0 |
| Non-Operating Income | $0 | $0 | $0 | $0 |
| Pre-Tax Income | $-112.6M | $-110.7M | $-21.9M | $-84.8M |
| Income Tax | $-2.7M | $-13.3M | $-12.2M | $0 |
| Continuing Ops | $-109.9M | $-97.3M | $-9.7M | $-84.8M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-109.9M | $-97.3M | $-9.7M | $-74.9M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-109.9M | $-97.3M | $-9.7M | $-74.9M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $207.5M | $242.2M | $249.9M | $357.5M |
| Cash & Equivalents | $35.1M | $25.6M | $58.2M | $197.5M |
| Prepaid Expenses | $4.4M | $5.4M | $6.8M | $5.2M |
| Other Current Assets | $168.1M | $211.2M | $184.9M | $154.8M |
| Long-Term Assets | $19.2M | $15.5M | $10.8M | $8.8M |
| PP&E (Net) | $6.9M | $5.2M | $3.9M | $2.8M |
| Operating Leases | $9.1M | $7.2M | $5.7M | $4.2M |
| Other LT Assets | $3.2M | $3.1M | $1.2M | $1.7M |
| Total Assets | $226.7M | $257.7M | $260.7M | $366.3M |
| Current Liabilities | $16.7M | $13.7M | $11.0M | $13.0M |
| Accounts Payable | $3.6M | $2.8M | $1.2M | $1.6M |
| Current Leases | $2.6M | $2.2M | $2.2M | $2.4M |
| Other Current Liab | $10.5M | $8.7M | $7.7M | $9.1M |
| Long-Term Liabilities | $11.0M | $8.8M | $6.6M | $4.2M |
| LT Operating Leases | $10.8M | $8.6M | $6.4M | $4.0M |
| Other LT Liab | $197.0K | $197.0K | $197.0K | $197.0K |
| Total Liabilities | $27.7M | $22.5M | $17.7M | $17.3M |
| Shareholders' Equity | $198.9M | $235.2M | $243.0M | $349.0M |
| Retained Earnings | $-412.3M | $-509.7M | $-519.4M | $-594.3M |
| AOCI | $-797.0K | $-136.0K | $130.0K | $174.0K |
| Treasury Stock | $0 | — | — | — |
| Total L&E | $226.7M | $257.7M | $260.7M | $366.3M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-109.9M | $-97.3M | $-9.7M | $-74.9M |
| Non-Cash Adjustments | $18.9M | $7.7M | $9.2M | $16.6M |
| Working Capital Changes | $-6.1M | $-1.3M | $-1.7M | $-1.7M |
| Cash from Operations | $-97.0M | $-91.0M | $-2.2M | $-60.1M |
| Capital Expenditures | $2.0M | $508.0K | $278.0K | $314.0K |
| Cash from Investing | $12.4M | $-36.7M | $32.2M | $30.7M |
| Cash from Financing | $84.3M | $118.1M | $2.7M | $168.7M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-314.0K | $-9.5M | $32.8M | $139.3M |
| Beginning Cash | $36.5M | $36.2M | $26.7M | $59.4M |
| Ending Cash | $36.2M | $26.7M | $59.4M | $198.7M |
The company's financial structure indicates a focus on research and development with no current revenue from sales, as it is in the pre-commercialization phase. Key operational segments include high-intensity research and development expenses ($56.1M in 2024) and general administrative functions ($28.7M), supported by significant cash flow from financing activities ($168.7M) to fund operations.
The company faces high risk of commercialization failure as it has no approved products and relies entirely on future regulatory approvals from the FDA or EMA. Significant revenue volatility is evident, dropping from $80.0M in 2024 to a net loss of $-74.9M in 2025, suggesting potential one-time accounting adjustments or lack of sustained commercial traction yet. The substantial operating losses ($-84.8M operating profit) and growing retained earnings deficit ($-594.3M) indicate heavy burn rates that could deplete cash reserves if financing dries up.
The company possesses a proprietary FULCIR technology platform designed for precise liver targeting, offering a unique mechanism of action distinct from competitors. A strong balance sheet with $197.5M in cash and equivalents provides substantial runway to advance multiple clinical candidates without immediate need for dilutive financing. The streamlined asset structure with low liabilities ($17.3M total) allows for agile decision-making in capital allocation.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.